Dakin P, et al. - Fasinumab, an anti-nerve growth factor monoclonal antibody, was prospectively evaluated regarding efficacy, general and joint safety in osteoarthritis (OA) pain. Researchers randomized 421 patients with moderate-to-severe OA pain (knee or hip) and history of inadequate response or intolerance to analgesics to fasinumab 1-mg, 3-mg, 6-mg, 9-mg or placebo every 4 weeks over 16 weeks and followed them to week 36. The 36-week study was completed by 342 of 421 patients. OA pain and function were improved with the administration of fasinumab, even in those benefitting little from previous analgesic. Further clinical development to explore the lowest doses of fasinumab is supported in view of favorable “benefit to risk” relationship.